Abstract
To evaluate the short-term cost effectiveness of insulin degludec/insulin aspart(IDegAsp) versus insulin glargine(IGlar) U100 + insulin aspart(IAsp) for the treatment of patients with type 2 diabetes with inadequately controlled on basal insulin in China.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
